Intracellular Translocation of Fluorescent Sphingolipids in Cultured Fibroblasts: Endogenously Synthesized Sphingomyelin and Glucocerebroside Analogues Pass through the Golgi Apparatus En Route to the Plasma Membrane

NAOMI G. LIPSKY and RICHARD E. PAGANO
Department of Embryology, Carnegie Institution of Washington, Baltimore, Maryland 21210

ABSTRACT When monolayer cultures of Chinese hamster lung fibroblasts are briefly incubated at 2°C with the fluorescent sphingolipid analogue, C6-NBD-ceramide (N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)] aminocaproyl sphingosine), fluorescent labeling of the mitochondria, endoplasmic reticulum, and nuclear envelope occur. During further incubation at 37°C, the Golgi apparatus, and later the plasma membrane, become intensely fluorescent. Within this period, the C6-NBD-ceramide is converted to equal amounts of fluorescent sphingomyelin and glucocerebroside (Lipsky, N. G., and R. E. Pagano, 1983, Proc. Natl. Acad. Sci. USA., 80:2608-2612). In the present study, the intracellular translocation of these metabolites and their subsequent appearance at the plasma membrane were investigated by fluorescence microscopy, the addition of the ionophore monensin, and the technique of “back exchange,” in which the amounts and types of fluorescent lipids present at the cell surface are identified after their transfer from the cell surface into recipient vesicles. In control cells, the amount of fluorescent glucocerebroside and sphingomyelin that could be removed from the cell surface by back exchange increased during incubation at 37°C, correlating with the increased fluorescence of the plasma membrane observed by microscopy. In the presence of 10 μM monensin, visible labeling of the plasma membrane was greatly diminished, whereas the Golgi apparatus became highly fluorescent and distended. The ability to remove fluorescent metabolites from the cell surface by back exchange was significantly but reversibly inhibited by monensin. Monensin also increased the total amount of fluorescent sphingomyelin, but not the glucocerebroside found in cells.

Subcellular fractions were assayed for their ability to convert radiolabeled and fluorescent ceramides to the corresponding sphingomyelins and glucocerebrosides. The activities of parallel fractions coincided, suggesting that the presence of the NBD moiety did not affect the cellular metabolism of ceramide. Furthermore, the major peak of sphingomyelin- and glucocerebroside-synthesizing activity appeared to coincide with an enriched Golgi fraction. These results strongly suggest that fluorescent sphingomyelin was not synthesized at the plasma membrane as has recently been suggested for endogenous sphingomyelin. Rather, both the sphingomyelin and glucocerebroside analogues were synthesized intracellularly from C6-NBD-ceramide and translocated through the Golgi apparatus to the cell surface.

The sites of lipid biosynthesis in animal cells and the mechanism(s) by which newly synthesized molecules are subsequently translocated to various intracellular membranes pose many fundamental but, as yet, unresolved questions for biochemists and cell biologists. Sphingomyelin, the predominant sphingolipid in many cell types, illustrates this point (1).
Two precursors for the synthesis of this lipid have been proposed. The long-standing evidence that the donor of the phosphorylcholine moiety of this molecule is CDP-choline (2-4) has recently been challenged in favor of phosphatidylcholine as the more likely donor (5-10). The site of sphingomyelin biosynthesis is also in dispute. The earliest studies (3) indicating that synthesis occurred in a microsomal fraction were based on the use of the nonnatural three-oligomannoside, and employed CDP-choline as the phosphatidylcholine donor. In a more recent study that used the naturally occurring d-erythroceramide and phosphatidylcholine precursors, Ullman and Radin (5) found activity in a crude liver microsomal fraction, and later Bernert and Ullman (6) established this for other tissues as well. Unfortunately, this crude microsomal fraction may have contained endoplasmic reticulum, Golgi apparatus, and plasma membrane. Marggraf et al. (8) found significant activity in a very light sucrose fraction, which they identified as plasma membrane. However, their later study (11) revealed the activity to actually be present in a Golgi fraction, a Golgi apparatus-plasma membrane fraction, and a plasma membrane fraction. They note in this report that 5'-nucleotidase, considered a marker for the plasma membrane, was found to an equal degree in the Golgi fraction (this has also been shown cytochemically (12)). Voeller and Kennedy (7), in an elegant study that established phosphatidylcholine as the appropriate precursor for sphingomyelin biosynthesis, went on to find significant synthetic activities in a plasma membrane fraction. However, this fraction was characterized on the basis of 5'-nucleotidase activity and was not assayed for the presence of Golgi membranes. Sphingomyelin synthetic activity has also been reported in mitochondria (13, 14).

In the present study, we address the issues of the site(s) of synthesis and route(s) of translocation of sphingolipids in cultured fibroblasts, by using a fluorescent analogue of ceramide. This approach has the advantage that the fluorescent ceramide and its metabolites may be visualized in living cells and quantified by reference to the intracellular distribution of these molecules may be obtained without fixation or cell disruption. These data can then be correlated with standard lipid biochemical analyses.

MATERIALS AND METHODS

Materials

Chemicals were purchased from the indicated sources: Eagle's minimal essential medium (Gibco Laboratories, Grand Island, NY); lectins (Vector Laboratories, Inc., Burlingame, CA); ovalbumin grade Y, UDP-glucose, UDP-galactose, sphingosine, and sphingosine-1-phosphocholine (Sigma Chemical Co., St. Louis, MO); dioleoyl phosphatidyl choline (DOPC) and N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl sphingosine (C6-NBD-ceramide); N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl sphingosine glucoside (C6-NBD-glucocerebroside); and N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl sphingosine-1-phosphocholine (C6-NBD-sphingomyelin) were synthesized from C6-NBD-aminocaproic acid and sphingosine, glucosylsphingosine, and sphingosine-1-phosphocholine, respectively (16). The concentrations of NBD-labeled lipids were determined fluorometrically (excitation 470 nm; emission 530 nm), and for C6-NBD-sphingomyelin, by phosphate analysis (17) as well. Palmitoyl sphingosine and [9,10-3H(N)] palmitoyl sphingosine were synthesized (16) and were entirely in the d-erythro form as judged by high-pressure liquid chromatography (studies performed by Dr. Yasuo Kishimoto, Johns Hopkins School of Medicine). [9,10-3H(N)] palmitoyl sphingosine was radiochemically pure by thin-layer chromatography.

Vesicle Preparation

Small unilamellar fluorescent vesicles were formed by ethanol injection (18): 23 mol% C6-NBD-ceramide-77% DOPC or 14 mol% C6-NBD-glucocerebroside or C6-NBD-sphingomyelin-85% DOPC were mixed, dried under nitrogen and then under reduced pressure, and made to 2.8 mM total lipids in ethanol. This mixture was injected into 13 vol of 10 mM HEPES-buffered calcium- and magnesium-free Puck's saline, dialyzed at 2°C overnight against this buffer, then diluted with HEPES-buffered Eagle's minimal essential medium (HMEM) to a final concentration of 0.5-10 nmol NBD lipid/mL. DOPC vesicles were prepared in the same manner, except the DOPC was made to 28 mM in ethanol, and the vesicles were dialyzed against HMEM and brought to a final concentration of 1.1 mM in HMEM.

Cell Culture and Incubations with Vesicles

Monolayer cultures of Chinese hamster V79 fibroblasts were grown to confluency in Eagle's minimal essential medium supplemented with glutamine, gentamicin, fungizone, streptomycin sulfate, penicillin G, and 12% horse serum in a water-saturated atmosphere of 5% CO2 in air. For fluorescent labeling, cultures were washed twice and incubated for 0.5 h in HMEM at 37°C, and then incubated with fluorescent vesicles in HMEM for 0.5 h at 2°C. Cultures were washed three times with HMEM, and then further incubated in HMEM at 37°C for the indicated times. For back-exchange studies, cultures were next incubated with DOPC vesicles for 15 min at 2°C, the medium was removed, and the incubation was repeated with additional DOPC vesicles. A parallel set of monolayer cultures was incubated with two changes of HMEM only. Cultures were washed three times with HMEM, scraped off the dish, and cellular lipids were extracted and analyzed (19). Where indicated, all of the above solutions contained 10 mM monensin. A 40 mM solution of monensin in ethanol was made fresh before use, diluted to 100 μM with HMEM, and then further diluted to a final concentration of 10 μM with the indicated incubation media. An equivalent amount of ethanol was present in all control solutions.

Microscopy

Fibroblasts were grown on rat tail collagen-coated glass coverslips, and incubated as described above. For Golgi apparatus co-localization studies, C6-NBD-ceramide-treated cells were first photographed for NBD fluorescence and then a Golgi apparatus-staining procedure (20) was followed with modifications (15). A Zeiss universal microscope (Carl Zeiss, Inc. New York) equipped with epi-illumination for fluorescence was used.

Thin-layer Chromatography

Cellular lipid extracts were applied to silica gel 60 thin-layer plates (Merck Co., Rahway, NJ) and developed in CHCl3/CH2OH/H2O (65:25:4). Fluorescent lipids were detected by ultraviolet illumination, and quantified by reference to synthetic standards with a Corning 750 scanning densitometer (Corning Medical and Scientific, Corning Glass Works, Medfield, MA).

Protein

Protein was estimated by absorbance at 280 nm and/or the Lowry procedure (21). There was good agreement between the two methods.
DNA Measurement

Aliquots of cell suspensions were precipitated in 0.2 N-perchloric acid and hydrolyzed, and DNA was estimated spectrophotometrically (22).

Subcellular Fractionation

Subcellular fractions were prepared by a modification of the procedure of Snider and Robbins (23). Cells were washed and scraped off the dish with PBS, centrifuged, and then resuspended in 10 mM Tris HCl, pH 7.4, 1 mM MgCl₂ at ~1 x 10⁶ cells/ml for 20 min at 2°C. The suspension was homogenized with 25 strokes in a loose-fitting Dounce homogenizer, 0.5 vol of 0.75 M sucrose-10 mM Tris HCl, pH 7.4, 1 mM MgCl₂, was added, and this was centrifuged at 600 g for 10 min. The supernatant was centrifuged at 100,000 g for 45 min in a SW41 rotor (Beckman Instruments, Inc., Fullerton, CA), and the pellet was resuspended in 0.2 M sucrose-10 mM Tris HCl, pH 7.4, 1 mM EDTA. This "membrane pellet" (0.8-1.2 mg of protein) was layered over a 1.7 ml gradient containing 1.7 ml each of 50, 40, 35, 30, 25, and 15% sucrose in 10 mM Tris HCl, pH 7.4, 1 mM EDTA. Fractions were centrifuged at 100,000 g for 45 min in a 50.2 Ti rotor (Beckman Instruments, Inc.), and pellets were resuspended in 10 mM Tris HCl, pH 7.4. Aliquots of each fraction were frozen and enzymatic activity was assayed within 24 h.

Enzyme and Marker Assays

PLASMA MEMBRANE: Monolayer cultures were incubated for 30 min at 2°C with 3H-labeled lactose transport was measured before and after protein precipitation. No difference was found in the activity profile except in the very-low-density region, indicating that all significant peaks represented protein-bound 3H.

GOLGI APPARATUS: Galactosyltransferase was measured by a modification of the procedure of Brotz et al. (25). The reaction mixture contained 40 mM sodium cacodylate, pH 7.0, 40 mM MnCl₂, 40 mM 2-mercaptoethanol, 17.5 mg/ml ovalbumin, 2 mM ATP, 0.4% Triton X-100, 1 μg/galactose-4,5-3H(N) UDP-galactose, 0.5 mM UDP-galactose, and ~10 μg of protein sample, in a fluid volume of 0.1 ml. After incubation at 37°C for 30 min, an additional 50 nmol UDP-galactose was added. Proteins were precipitated and washed with trichloroacetic acid at 2°C, digested with 10 N NaOH, and neutralized with 20 N HCl. Then 5 ml of Aquasol was added, and radioactivity was measured. The tyrosine amino acid marker 8-hydroxyinositide was assayed as described (24).

SPHINGOMYELIN AND GLUCOCEREBROSIDE SYNTHESIS ASSAYS: Sphingomyelin synthesis from C₃-NBD-ceramide was initially assayed by the method of Voelker and Kennedy (7). However, to avoid the use of detergents, an alternative assay system was used that gave identical results. This procedure is a modification of that of Costantino-Ceccarini and Castelli (26). C₃-NBD-ceramide or [9,10-3H(N)] palmitoyl sphingosine was mixed with DOPC, and the lipids were deacetylated. To this was added a solution of 130 mM KCl, 10 mM Tris HCl, pH 7.4, for final lipid concentrations of 670 μM ceramide and 1.37 mM DOPC. After 50 min at 25°C, the mixture was sonicated in a Branson 12 water bath sonicator (Branson Sonic Power Co., Danbury, CT) until completely resuspended (5-10 s). Assay reagents were added to the sample (5-10 μg of protein), then the reaction was started with the addition of liposomes. 20 nmol of C₃-NBD-ceramide or [9,10-3H(N)] palmitoyl sphingosine (2 x 10⁶ cpm) and 40 nmol of DOPC were present in each assay. After incubation of the reaction mixture at 37°C for 15 min, lipids were extracted and applied to silica gel 60 plates. NBD lipids were separated in CHCl₃/CH₃OH/H₂O/NH₄OH (72:48:9:2) (6). Fluorescent spots were quantified by scanning densitometry. 3H-labeled lipids were separated in CHCl₃/CH₃OH/H₂O/10% NH₄OH (72:48:9:2). Fluorescent spots were quantified by scanning densitometry. 3H-labeled lipids were separated in CHCl₃/CH₃OH/H₂O/10% NH₄OH (72:48:9:2). Fluorescent spots were quantified by scanning densitometry. 3H-labeled lipids were separated in CHCl₃/CH₃OH/H₂O/10% NH₄OH (72:48:9:2). Fluorescent spots were quantified by scanning densitometry.

Calculation of results

The percent of NBD lipids removed by back exchange was calculated as 100 x (1 - amount present with back exchange/amount present without back exchange). All values were on a per DNA basis. Statistical significance was evaluated with a Student's t test.

RESULTS

Monensin Affects Intracellular Distribution of Fluorescence

When fibroblast monolayers were incubated briefly with C₃-NBD-ceramide-containing vesicles at 2°C, washed, and warmed 30 min at 37°C in HMEM, intense labeling was seen in a perinuclear region and to a lesser degree in mitochondria and endoplasmic reticulum (Fig. 1A). Within 2 h, the plasma membrane became visibly labeled (Fig. 1C). In the presence of 10 μM monensin, two major differences were noted. First, the bright, perinuclear fluorescence seen after 30 min became even more intense, and appeared to occupy a larger, more diffuse area (Fig. 1B). In addition, mitochondria assumed a spherical shape, rather than their more typical elongated "threadlike" form. The second major difference was the significant reduction in plasma membrane labeling seen after 2 h at 37°C (Fig. 1D). Cell viability, as assessed by trypan blue exclusion, was unaffected by C₃-NBD-ceramide or monensin treatments.

The Intensely Labeled Region Is the Golgi Apparatus

We have previously demonstrated that the perinuclear region described in Fig. 1A corresponds to the Golgi apparatus (15). To determine the identity of the highly labeled area seen in the presence of monensin (Fig. 1B and D), we carried out co-localization studies with rhodamine-labeled wheat germ agglutinin, a lectin that preferentially labels the Golgi apparatus (20). Fig. 2 demonstrates the co-localization of NBD fluorescence with the lectin. It was apparent that the NBD-labeled structure corresponded to the Golgi apparatus in monensin-treated cells.

Arrival of NBD Lipids at the Plasma Membrane

The identity of the compounds present at the plasma membrane of fluorescently labeled monolayers was investigated using "back exchange." In this procedure C₃-NBD-lipids present in the plasma membrane of labeled cells are transferred into nonfluorescent recipient DOPC vesicles (27). The vesicles and cells can be separated, and the fluorescent lipids present in each can be extracted and quantified. This technique was applied in the present study in an attempt to remove and analyze those NBD lipids present in the plasma membranes of C₃-NBD-ceramide-labeled cells.

Several features of back exchange were investigated before the technique was applied to C₃-NBD-ceramide-treated cells (Table I). This data was obtained from cells that had been labeled with exogenously supplied C₃-NBD-sphingomyelin or C₃-NBD-glucocerebroside rather than by allowing these lipids to be synthesized endogenously by metabolism of C₃-NBD-ceramide. At 2°C, these compounds reside exclusively in the plasma membrane as determined by fluorescence microscopy (reference 28 and data not shown) and thus provide a model system for testing back exchange efficiency. The maximum amount of each compound which could be removed from the plasma membrane by this method was 88% for the C₃-NBD-sphingomyelin and 85% for C₃-NBD-glucocerebroside. The presence of monensin in the incubation medium did not affect the efficiency of back exchange. These results indicated that back exchange should efficiently remove almost all of the NBD-sphingomyelin and NBD-glucocerebroside that...
FIGURE 1 Intracellular fluorescence in the presence and absence of monensin: cells were incubated with C6-NBD-ceramide containing vesicles at 2°C, washed, and incubated at 37°C in HMEM for 30 min (A and B) or 2 h (C and D). For B and D, all steps were in the presence of 10 μM monensin. Bar, 10 μm.

might appear at the plasma membrane following the metabolism of C6-NBD-ceramide. When cultures labeled for 60 min at 2°C with C6-NBD-sphingomyelin or C6-NBD-glucocerebroside were washed and incubated for 30 min at 37°C, plasma membrane labeling decreased, while internal or cytoplasmic fluorescence became visible (reference 28 and data not shown). Following this incubation, the amount of fluorescent lipid which could be removed by back exchange decreased from ~90% to ~70% for NBD-sphingomyelin and from ~90% to ~60% for NBD-glucocerebroside (data not shown). Fluorescence microscopy of these cells indicated that after back exchange, no plasma membrane fluorescence remained, while strong cytoplasmic fluorescence was still visible. These results suggest that NBD-lipids inside the cell are much less accessible to back exchange. Similar findings have previously been reported using a fluorescent analogue of phosphatidylcholine (27).

Fig. 3 shows the results of a back exchange experiment using cells that were first incubated with vesicles containing C6-NBD-ceramide for 60 min at 2°C, washed, and then incubated at 37°C. At various intervals they were either subjected to back exchange, or, for controls, incubated in HMEM. Cell lipids were extracted and separated by thin-layer chromatography. The amount of each fluorescent lipid present in the control and back exchanged cells was determined and normalized to cell DNA, and the percent removed
FIGURE 2. Co-localization of fluorescence in the presence of monensin to the Golgi apparatus: cells were incubated with C₄-NBD-ceramide-containing vesicles at 2°C, washed, and incubated in HMEM at 37°C for 0.5 h. They were then photographed for NBD fluorescence (A). Monolayers were then treated as described in Materials and Methods with Golgi apparatus staining rhodamine-labeled wheat germ agglutinin, and the same field was rephotographed for rhodamine fluorescence (B). All prefixation steps were in the presence of 10 μM monensin. Bar, 10 μm.

Table I

|                    | -DOPC Vesicles | +DOPC Vesicles | % Removed by back exchange |
|--------------------|----------------|----------------|---------------------------|
| A. Cr-NBD-sphingomyelin |                |                |                           |
| Control            | 2,828 ± 171    | 349 ± 31       | 88                        |
| 10 μM monensin     | 3,039 ± 152    | 238 ± 14       | 92                        |
| B. Cr-NBD-glucocerebroside |            |                |                           |
| Control            | 2,823 ± 16     | 428 ± 10       | 85                        |
| 10 μM monensin     | 2,958 ± 84     | 530 ± 23       | 82                        |

Cells were incubated for 0.5 h at 2°C with vesicles containing either (A) C₄-NBD-sphingomyelin or (B) C₄-NBD-glucocerebroside. They were washed and incubated at 2°C with HMEM (−DOPC vesicles), or subjected to back exchange (+DOPC vesicles), as described in Materials and Methods. Where indicated, all steps were in the presence of 10 μM monensin. Values are pmol NBD lipid/mg cell DNA, and represent mean ± SD of three independent experiments.

It is difficult to establish whether back exchange overestimates the amount of NBD-lipid present at the plasma membrane by removing some fluorescent lipid from the cell interior. This may be the case since at early stages of the 37°C incubation (e.g., 5 min), 15–20% of the NBD-ceramide, and 25–30% of each NBD-sphingomyelin and -glucocerebroside could be removed by back exchange (Fig. 3), even though no plasma membrane labeling could be seen by fluorescence microscopy. This absence of plasma membrane labeling was not because the levels of NBD-metabolites were too low to be seen since exogenously supplied C₄-NBD-ceramide or -sphingomyelin present in the plasma membrane at these concentrations was readily observed. While some removal of NBD-lipids from the cell interior may have occurred during back exchange, this can only cause an overestimate of the amounts of NBD-lipids present at the plasma membrane. Such an overestimate does not alter the conclusion suggested by Fig. 3 and related experiments in Table II (see below), namely that the fluorescent metabolites are synthesized within the cell, and subsequently transported to the cell surface.
Monensin Inhibits Plasma Membrane Labeling in a Reversible Manner

After 30 min at 37°C in the presence of monensin, back exchange removed significantly less of the fluorescent lipids (Table II). Only 16% of NBD-glucocerebroside was removed in the presence of the inhibitor, in contrast to 46% in its absence, even though the total amount of NBD-glucocerebroside was unchanged (see below). Similarly, only 25% of NBD-sphingomyelin was removed in monensin-treated cells, whereas 51% was removed from controls. Again, only 16% of the C₆-NBD-ceramide could be removed in either case. These findings are in agreement with the fluorescence microscopic observations shown in Fig. 1. This effect of monensin was significant after 15 min at 37°C and persisted for at least 45 min (data not shown). The reversibility of the monensin effect is also demonstrated in Table II. When monensin was washed out midway through the warm-up period, the amount of NBD-glucocerebroside that could be removed from the plasma membrane by back exchange increased significantly. The amount of NBD-sphingomyelin that could be removed also showed a slight, though not statistically significant, increase. The total levels of metabolites during the reversal remained the same as in the monensin-treated cells (see below), indicating that the increase in amount of NBD-lipids that could be removed by back exchange was not due to new synthesis.

Monensin Treatment Results in Elevated NBD-Sphingomyelin Levels

The effect of monensin on overall C₆-NBD-ceramide metabolism was investigated by measuring the levels of fluorescent metabolites present in cells after various times at 37°C, in the presence and absence of monensin. Table III demonstrates that although monensin significantly increased the level of NBD-sphingomyelin during the warming period, C₆-NBD-ceramide levels decreased slightly and NBD-glucocerebroside levels were unaffected.

Ability of Subcellular Fractions to Catalyze the Synthesis of Sphingomyelin and Glucocerebroside from Either C₆-NBD-Ceramide or [³H]Palmitoylsphingosine

To assess the possible effect of the NBD label on ceramide utilization, we performed in vitro studies to compare C₆-NBD-ceramide with an isotopically labeled ceramide. Cell homogenates were subjected to sucrose density-gradient centrifugation, and the subcellular fractions were assayed for the ability to convert C₆-NBD-ceramide or [⁹,₁₀-³H(N)] palmitoylsphingosine to the corresponding sphingomyelin and glucocerebroside. Fig. 4a demonstrates the similarity between

---

**Figure 3** Ability of back exchange to remove NBD-lipids after incubation at 37°C: Cells were incubated with C₆-NBD-ceramide-containing vesicles at 2°C, washed, and incubated at 37°C in HMEM for the indicated time. They were then subjected to back exchange and lipids were extracted and results were calculated, as described in Materials and Methods. Points represent the mean ± SD of three to six independent experiments. (▲) C₆-NBD-ceramide; (■) NBD-sphingomyelin; (□) NBD-glucocerebroside.

**Table II**

Effect of Monensin on the Back Exchange of Endogenously Synthesized NBD Lipids

|                  | C₆-NBD-ceramide | NBD-glucocerebroside | NBD-sphingomyelin |
|------------------|-----------------|----------------------|-------------------|
| A. Control       | 16 ± 11         | 46 ± 10              | 51 ± 10           |
| B. Monensin      | 16 ± 10         | 16 ± 12*             | 25 ± 12*          |
| C. Reversal      | 8 ± 16          | 31 ± 7*              | 31 ± 12*          |

* Different from monensin-treated (P < 0.05).

---

**Table III**

NBD Lipid Levels in the Presence and Absence of Monensin

| NBD Lipid Levels | Min at 37°C |
|------------------|-------------|
|                  | 0          | 5          | 15         | 30         |
|                  | +          | +          | +          | +          |
| C₆-NBD-ceramide  | 96 ± 0     | 93 ± 2     | 68 ± 5     | 58 ± 4     | 44 ± 14 | 33 ± 10 | 23 ± 8 | 19 ± 4 |
| NBD-glucocerebroside | —     | —          | 19 ± 6     | 20 ± 6     | 27 ± 9 | 28 ± 8 | 37 ± 8 | 31 ± 7 |
| NBD-sphingomyelin | —          | —          | 12 ± 1     | 22 ± 1*    | 28 ± 6 | 39 ± 3* | 40 ± 4 | 49 ± 4* |

Cells were incubated with C₆-NBD-ceramide-containing vesicles at 2°C, washed, and incubated in HMEM at 37°C for the indicated times in the absence (−) or presence (+) of 10 μM monensin. Fluorescent lipids were extracted and quantified. The percent of total fluorescence due to each metabolite was calculated. Results are the mean ± SD of three to five independent experiments.

* Indicates different from control (P < 0.05).

---
lysosomes were found at 35–40% and 10% sucrose (data not shown). It is unlikely that mitochondria were present at the density of the Golgi fraction (31), but some smooth or rough endoplasmic reticulum may have been present.

**DISCUSSION**

We have previously shown that C₆-NBD-ceramide is metabolized to fluorescent glucocerebroside and sphingomyelin in cultured fibroblasts at 37°C (15). The cells are initially labeled in the mitochondria, endoplasmic reticulum, and nuclear envelope, but as metabolism progresses, the Golgi apparatus becomes intensely labeled, and later, the plasma membrane becomes strongly fluorescent. The results of the present study are consistent with the hypothesis that both fluorescent sphingomyelin and glucocerebroside are synthesized inside the cell and are translocated through the Golgi apparatus before arriving at the plasma membrane. This reasoning is based on data obtained from studies conducted in intact, living cells using the fluorescent ceramide precursor in the presence and absence of the ionophore monensin.

Fluorescence microscopy revealed that if cells that had been labeled with C₆-NBD-ceramide at 2°C were washed and warmed to 37°C, the Golgi apparatus became intensely fluorescent. After longer periods at 37°C, the plasma membrane became strongly labeled with both NBD-sphingomyelin and NBD-glucocerebroside (Table II). The fraction of each metabolite present in the cell that could be removed by back exchange increased with time at 37°C, suggesting that both were being delivered to the plasma membrane from an intracellular site. If either compound were synthesized at the plasma membrane, such a time delay would not be expected.

Because the Golgi apparatus was implicated by microscopy as a participant in this metabolism, further studies were conducted in monensin-treated cells. It is known that monensin has multiple intracellular effects, but is most remarkable for blocking the transport of secretory glycoproteins out of the Golgi apparatus, acting somewhere between the proximal and distal regions (for review, see reference 32). Recently, it has been shown to block the further glycosylation of cerebrosides (33, 34). Fluorescence microscopy of NBD-ceramide labeled cells in the presence of monensin revealed the striking morphological changes in the Golgi apparatus characteristic of this ionophore. Light and electron microscopy of fixed cells have established that monensin treatment leads to a swollen, vesiculated Golgi apparatus (32), but to our knowledge, this is the first demonstration of monensin’s effects in living cells.

Monensin treatment markedly reduced visible plasma membrane labeling (Fig. 1D), and inhibited the arrival of both NBD-glucocerebroside and NBD-sphingomyelin at the cell surface (Table II) although cellular levels of the latter actually increased (Table III). The finding that NBD-glucocerebroside was inhibited from appearing at the plasma membrane was not unexpected as most evidence indicates that glycosylating enzymes are localized to microsomal or Golgi fractions (2, 33–36). The inhibition of NBD-sphingomyelin transport to the cell surface by monensin was more significant, inasmuch as the exact site of sphingomyelin biosynthesis is subject to dispute.

The finding that monensin caused the cellular accumulation of NBD-sphingomyelin while retarding its appearance at the plasma membrane most strongly suggested that NBD-sphingomyelin was synthesized intracellularly and transported through the Golgi apparatus to the plasma membrane. Were it to be synthesized at the plasma membrane, several

---

**Figure 4** Sucrose gradient profiles of enzymatic activities and markers of subcellular fractions. Cells were subjected to subcellular fractionation and fractions were assayed for the indicated activities. Representative gradients are shown. The ordinate represents specific activity relative to that of the starting “membrane pellet,” calculated in cpm/OD₂₅₀ or fluorescence units/OD₂₅₀. ¹²⁵I-WGA is based on precipitated cpm/μg protein. (a) [³H]Sphingomyelin synthesis (○); NBD-sphingomyelin synthesis (●); (b) [³H]-glucocerebroside synthesis (●); NBD-glucocerebroside synthesis (○); (c) galactosyl transferase (Golgi marker) (○); ¹²⁵I-wheat germ agglutinin (plasma membrane marker) (●).
findings should have resulted in this system. One might expect that back exchange would remove more NBD-sphingomyelin, and more rapidly than it would NBD-glucocerebroside. However, both compounds were removed in a parallel fashion. In the presence of monensin, which significantly raised NBD-sphingomyelin levels, back exchange reveals the appearance of both isotopically labeled glycosphingolipids (33, 34) and fluorescent glucocerebroside at the cell membrane. However, metabolites of the glucosylceramide and phosphatidylcholine by a microsomal cholinephosphotransferase. Biochim. Biophys. Acta. 666:99-109. 27. Struck, D. K., and R. E. Pagano. 1980. Insertion of fluorescent phospholipids into the plasma membrane of cultured fibroblasts. Biochim. Biophys. Acta. 694:1-73. 28. Lipsky, N. G., and R. E. Pagano. 1984. Fluorescent sphingomyelin labels the plasma membrane of cultured fibroblasts. Biochim. Biophys. Acta. 785:1-7.

In conclusion, by using a fluorescent ceramide analogue we have observed sphingolipid metabolism in a living system without fixation or disruption of cells. Our results suggest that both the NBD-sphingomyelin and fluorescent sphingomyelin were synthesized intracellularly from C2-NBD-ceramide, and were then translocated through the Golgi apparatus to the cell surface. Importantly, fluorescent sphingomyelin was apparently not synthesized at the plasma membrane as has recently been suggested for endogenous sphingomyelin (7, 8). However, at present we do not know how accurately the metabolism and intracellular translocation of C2-NBD-ceramide may reflect the behavior of endogenous ceramide. Our findings that (a) exogenously supplied C2-NBD-ceramide was metabolized to the expected fluorescent products in intact cells; (b) C2-NBD-ceramide and [3H]ceramide were metabolized to equal extents by subcellular fractions; and (c) monensin inhibits the appearance of both isotopically labeled glycosphin-
golipids (33, 34) and fluorescent glucocerebroside at the cell surface suggest that the approach with fluorescent ceramide will be useful in further studies of sphingolipid metabolism and translocation in cells.

We thank Dr. Yasuo Kishimoto for performing the high-pressure liquid chromatography studies.

This work was supported by grant GM-22942 from the U.S. Public Health Service. Dr. Lipsky was supported by a postdoctoral fellowship (GM-08848) from the National Institutes of Health.